Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 18;4(8):1175-1178.
doi: 10.1016/j.ekir.2019.05.002. eCollection 2019 Aug.

Myelodysplastic Syndrome in Hemodialysis Patients

Hamza Ayari  1 , Florence Pasquier  2 , Khalil El Karoui  3   4 , Marion Sallée  5 , Stanislas Faguer  6 , Thierry Krummel  7 , Laurence Nicolet  8 , Thibault Dolley-Hitze  9 , Vincent Audard  3   4 , Christophe Ridel  10 , Jean-Baptiste Micol  2 , Maxime Touzot  10
Affiliations

Myelodysplastic Syndrome in Hemodialysis Patients

Hamza Ayari et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation data in onset of dialysis after diagnosis of MDS (MDS-1) and onset of dialysis before diagnosis of MDS (MDS-2) groups. (a) Neutrophil, (b) hemoglobin, and (c) platelet counts in MDS-1 patients and controls at M0 and M12 of dialysis, and in MDS-2 patients at diagnosis (M0). Data are expressed as mean ± SD. **P < 0.01; ns, nonsignificant (Mann−Whitney test). Principal component analysis (PCA) was used to define which biological parameters contributed the most to each profile (MDS-1, MDS2, and control). (d) Variable correction plots. ERI, erythropoietin resistance index; MCV, mean corpuscular volume; MDS, myelodysplastic syndrome.
Figure 2
Figure 2
Survival after 5 years of dialysis. Graph represents survival after 5 years of dialysis for all patients (black), onset of dialysis after diagnosis of MDS (MDS-1) patients (red), and onset of dialysis before diagnosis of MDS (MDS-2) patients (gray). Difference in survival was not statistically significant (P = 0.363, log-rank test). MDS, myelodysplastic syndrome.
See this image and copyright information in PMC

References

    1. Erslev A.J., Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int. 1997;51:622–630. - PubMed
    1. Bamgbola O.F. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int. 2011;80:464–474. - PubMed
    1. Gangat N., Patnaik M.M., Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91:76–89. - PubMed
    1. Marcelli D., Bayh I., Merello J.I. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients. Kidney Int. 2016;90:192–202. - PubMed
    1. Li W., Morrone K., Kambhampati S. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Leukemia. 2016;30:536–544. - PubMed

LinkOut - more resources